Gene expression profile in NB4 cells treated with STI571, all-trans-retinoic acid, or the combination of the two compounds
| (group) Gene . | Control . | STI571 . | ATRA . | STI571 + ATRA . |
|---|---|---|---|---|
| (1) | ||||
| MCP-1 | 89 ± 11 | 330 ± 5 | 957 ± 22 | 2112 ± 289 |
| MRP-8 | < 50 | < 50 | 212 ± 16 | 759 ± 36 |
| MRP-14 | < 50 | < 50 | 251 ± 1 | 716 ± 5 |
| CRF receptor 1 | < 50 | < 50 | < 50 | 65 ± 5 |
| (2) | ||||
| IRF-1 | 63 ± 5 | 88 ± 3 | 234 ± 4 | 250 ± 5 |
| Neuromodulin | < 50 | < 50 | 130 ± 14 | 84 ± 54 |
| BDNF | < 50 | < 50 | 169 ± 6 | 204 ± 27 |
| (3) | ||||
| IL-13 | < 50 | 866 ± 18 | 102 ± 3 | < 50 |
| IL-4 | < 50 | 352 ± 27 | 90 ± 11 | < 50 |
| IL-6 | 193 ± 43 | 3760 ± 130 | 203 ± 29 | 162 ± 1 |
| GM-CSF | < 50 | 127 ± 8 | 64 ± 11 | < 50 |
| IFNγ | < 50 | 150 ± 44 | 63 ± 1 | < 50 |
| Wnt-5A | < 50 | 606 ± 5 | < 50 | < 50 |
| Ephrin B rec.1 | < 50 | < 50 | 68 ± 12 | < 50 |
| IGF bp 3 | < 50 | 63 ± 5 | 64 ± 9 | < 50 |
| IL-17 | < 50 | 162 ± 5 | 99 ± 3 | 67 ± 0 |
| IL-8 | 65 ± 2 | 380 ± 5 | 110 ± 3 | 204 ± 5 |
| TKT precursor | < 50 | 205 ± 33 | < 50 | 65 ± 9 |
| MIF | < 50 | < 50 | 209 ± 16 | < 50 |
| (4) | ||||
| NGF receptor | 624 ± 34 | 233 ± 33 | 758 ± 93 | 352 ± 55 |
| Thymosin β3 | 523 ± 14 | 150 ± 1 | 443 ± 32 | 120 ± 2 |
| HBNF 1 | 289 ± 31 | 138 ± 4 | 341 ± 6 | 101 ± 6 |
| (5) | ||||
| TNFα | 503 ± 106 | 414 ± 30 | 96 ± 6 | < 50 |
| (group) Gene . | Control . | STI571 . | ATRA . | STI571 + ATRA . |
|---|---|---|---|---|
| (1) | ||||
| MCP-1 | 89 ± 11 | 330 ± 5 | 957 ± 22 | 2112 ± 289 |
| MRP-8 | < 50 | < 50 | 212 ± 16 | 759 ± 36 |
| MRP-14 | < 50 | < 50 | 251 ± 1 | 716 ± 5 |
| CRF receptor 1 | < 50 | < 50 | < 50 | 65 ± 5 |
| (2) | ||||
| IRF-1 | 63 ± 5 | 88 ± 3 | 234 ± 4 | 250 ± 5 |
| Neuromodulin | < 50 | < 50 | 130 ± 14 | 84 ± 54 |
| BDNF | < 50 | < 50 | 169 ± 6 | 204 ± 27 |
| (3) | ||||
| IL-13 | < 50 | 866 ± 18 | 102 ± 3 | < 50 |
| IL-4 | < 50 | 352 ± 27 | 90 ± 11 | < 50 |
| IL-6 | 193 ± 43 | 3760 ± 130 | 203 ± 29 | 162 ± 1 |
| GM-CSF | < 50 | 127 ± 8 | 64 ± 11 | < 50 |
| IFNγ | < 50 | 150 ± 44 | 63 ± 1 | < 50 |
| Wnt-5A | < 50 | 606 ± 5 | < 50 | < 50 |
| Ephrin B rec.1 | < 50 | < 50 | 68 ± 12 | < 50 |
| IGF bp 3 | < 50 | 63 ± 5 | 64 ± 9 | < 50 |
| IL-17 | < 50 | 162 ± 5 | 99 ± 3 | 67 ± 0 |
| IL-8 | 65 ± 2 | 380 ± 5 | 110 ± 3 | 204 ± 5 |
| TKT precursor | < 50 | 205 ± 33 | < 50 | 65 ± 9 |
| MIF | < 50 | < 50 | 209 ± 16 | < 50 |
| (4) | ||||
| NGF receptor | 624 ± 34 | 233 ± 33 | 758 ± 93 | 352 ± 55 |
| Thymosin β3 | 523 ± 14 | 150 ± 1 | 443 ± 32 | 120 ± 2 |
| HBNF 1 | 289 ± 31 | 138 ± 4 | 341 ± 6 | 101 ± 6 |
| (5) | ||||
| TNFα | 503 ± 106 | 414 ± 30 | 96 ± 6 | < 50 |
NB4 cells (2 × 105 cells/mL) were treated with STI571 (5 × 10−6 M), ATRA (10−7 M), or the combination of the two compounds for 2 days. RNA was isolated, reverse transcribed in the presence of 32P dATP, and used as a probe to hybridize complementary DNA microarrays on nylon membranes. Results are the mean ± SD of 2 replicate spots and are expressed in arbitrary units following densitometric analysis of the microarray image. The notation < 50 indicates spots with a signal equivalent to the background. Genes were subdivided into 5 groups according to the criteria defined in the text.
At the time of harvesting, the following parameters were measured in parallel cultures (mean ± SD of 3 culture flasks): No. cells (× 1000); control, 460 ± 10; STI571, 421 ± 11; ATRA, 350 ± 8; STI571 ± ATRA, 290 ± 8; viability (%): control, 87 ± 1; STI571, 84 ± 1; ATRA, 84 ± 2; STI571 + ATRA, 80 ± 1; NBT-reducing activity O.D. (540 nm): control, 0.215; STI571, 0.210; ATRA, 0.410; STI571 + ATRA, 0.920.
ATRA indicates all-trans-retinoic acid; MCP-1, monocyte chemotactic protein 1 precursor; MRP, migration-inhibitory factor-related protein; CRF receptor 1, corticotropin-releasing factor receptor 1 precursor; IRF-1, interferon regulatory factor 1; BDNF, brain-derived neurotrophic factor; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon γ; Ephrin B rec.1, ephrin type-B receptor 1 precursor; IGF bp 3, insulinlike growth factor binding protein 3; TKT precursor, neurotrophic tyrosine kinase receptor-related 3; MIF, migration-inhibitory factor; NGF, neurotrophic growth factor; HBNF 1, heparin-binding neurite outgrowth promoting factor 1; TNFα, tumor necrosis factor α.